Later Reg Trumps Contract Clause Again
Client Alert | 1 min read | 07.28.05
In Fluor Hanford Inc. v. U.S. (July 1, 2005), the Court of Federal Claims upheld the contracting officer's disallowance of 20 percent of the costs of successfully defending a False Claims Act case, holding that a specific contractual provision in a 1996 DOE M&O contract promising to reimburse the contractor for all costs of civil actions that arose from conditions that existed before the contractor assumed responsibility for the plant was effectively trumped by 2001 changes to the FAR imposing an 80 percent limit on the allowability of legal fees incurred in the successful defense of qui tam actions under the False Claims Act in which the Government did not intervene. The decision relies on the Federal Circuit's analysis in Boeing N. Am., Inc. v. Roche, 298 F.3d 1274 (Fed. Cir. 2002), and, with the ASBCA decision in Southwest Marine decided in February, this case reflects a disturbing trend to ignore specific contractual provisions about allowability in favor of substantive regulatory changes made years after the contract was awarded that the Federal Circuit characterized as a "clarification" with retroactive effect.
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
